Patents by Inventor Wayne Front March
Wayne Front March has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100185066Abstract: An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence traveling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio of the first fluorescence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.Type: ApplicationFiled: January 24, 2010Publication date: July 22, 2010Inventor: Wayne Front MARCH
-
Patent number: 7653424Abstract: An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence traveling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio of the first fluorescence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.Type: GrantFiled: March 16, 2006Date of Patent: January 26, 2010Assignee: Eyesense AGInventor: Wayne Front March
-
Patent number: 6980842Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: GrantFiled: October 11, 2002Date of Patent: December 27, 2005Assignee: NovartisInventors: Wayne Front March, Mary Flowers Mowery-McKee
-
Patent number: 6850786Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, inidicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: GrantFiled: September 3, 2003Date of Patent: February 1, 2005Assignee: Novartis AGInventor: Wayne Front March
-
Publication number: 20040152963Abstract: An apparatus for measuring ocular and/or blood glucose levels comprises (a) an irradiating means (10) for irradiating light onto the eye (1) of a user from outside the cornea of the eye to excite an ocular glucose sensor in contact with an ocular fluid, said sensor being able to emit a total fluorescence having first and a second wavelength bands; (b) an optical path splitting means (11) for splitting said total fluorescence into a first fluorescence and a second fluorescence, said first fluorescence and said second fluorescence travelling along first and second optical paths; (c) a first detecting means (14) located in the first optical path; (d) a second detecting means (17) located in the second optical path; (e) a calculating means for calculating the intensity ratio or the first fluorecence to the second fluorescence and for determining an ocular glucose concentration in the ocular fluid; and (f) an arithmetic means for converting the ocular glucose concentration into a blood glucose concentration.Type: ApplicationFiled: March 26, 2004Publication date: August 5, 2004Inventor: Wayne Front March
-
Publication number: 20040059207Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, inidicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: ApplicationFiled: September 3, 2003Publication date: March 25, 2004Inventor: Wayne Front March
-
Patent number: 6681127Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: GrantFiled: February 15, 2001Date of Patent: January 20, 2004Assignee: Novartis AGInventor: Wayne Front March
-
Publication number: 20030045783Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: ApplicationFiled: October 11, 2002Publication date: March 6, 2003Inventors: Wayne Front March, Mary Flowers Mowery-McKee
-
Publication number: 20020007113Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: ApplicationFiled: July 6, 2001Publication date: January 17, 2002Inventors: Wayne Front March, Mary Flowers Mowery-McKee
-
Publication number: 20010034500Abstract: An ophthalmic lens comprising a receptor moiety can be used to determine the amount of an analyte in an ocular fluid. The receptor moiety can bind either a specific analyte or a detectably labeled competitor moiety. The amount of detectably labeled competitor moiety which is displaced from the receptor moiety by the analyte is measured and provides a means of determining analyte concentration in an ocular fluid, such as tears, aqueous humor, or interstitial fluid. The concentration of the analyte in the ocular fluid, in turn, indicates the concentration of the analyte in a fluid or tissue sample of the body, such as blood or intracellular fluid.Type: ApplicationFiled: February 15, 2001Publication date: October 25, 2001Inventor: Wayne Front March
-
Patent number: 3958560Abstract: A unique glucose sensor to determine the glucose level in patients, for example, for use in treating or diagnosing diabetes. The patient's eye is automatically scanned using a source of radiation at one side of the patient's cornea. A sensor located at the other side of the cornea detects the radiation that passed through the cornea. The level of glucose in the bloodstream of the patient is a function of the amount of radiation detected at the other side of the cornea of the patient. The result is transmitted to a remote receiver that is coupled to a readout device to thereby provide non-invasive glucose determinations.Type: GrantFiled: November 25, 1974Date of Patent: May 25, 1976Inventor: Wayne Front March